ixekizumab (Taltz)
ixekizumab is an FDA-licensed reference biologic from Eli Lilly and Company. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2016
Reference approved
Reference product
Taltz ixekizumab
Eli Lilly and Company
- Approved
- Mar 22, 2016
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Molecular structure
Experimental 3D structure for ixekizumab from the RCSB Protein Data Bank (PDB 6NOU).
Interactive biological assembly from PDB entry 6NOU. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here — no need to leave the page.
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for ixekizumab, in chronological order.
Reference approval
Approval date of the reference ixekizumab product.
10 yr 4 mo ago
Frequently asked questions
Are there biosimilars approved for ixekizumab (Taltz)?
No 351(k) biosimilars or interchangeable biosimilars referencing ixekizumab are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.